Bristol-Myers Squibb Co
NYSE:BMY

Watchlist Manager
Bristol-Myers Squibb Co Logo
Bristol-Myers Squibb Co
NYSE:BMY
Watchlist
Price: 52.305 USD 0.68%
Market Cap: 106.5B USD

Operating Margin
Bristol-Myers Squibb Co

33.5%
Current
26%
Average
6.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
33.5%
=
Operating Profit
16.1B
/
Revenue
48B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Bristol-Myers Squibb Co
NYSE:BMY
105.6B USD
34%
US
Eli Lilly and Co
NYSE:LLY
967.6B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
488.8B USD
27%
CH
Roche Holding AG
SIX:ROG
249.5B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
211.7B GBP
24%
CH
Novartis AG
SIX:NOVN
206.5B CHF
33%
US
Merck & Co Inc
NYSE:MRK
252.3B USD
38%
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
42%
IE
Endo International PLC
LSE:0Y5F
202.5B USD
11%
US
Pfizer Inc
NYSE:PFE
146.1B USD
29%
No Stocks Found

Bristol-Myers Squibb Co
Glance View

Bristol-Myers Squibb Co., with its storied history stretching back over 100 years, has cemented its place among the giants in the pharmaceutical industry. Rooted in a relentless quest for innovation, the company is a powerhouse in biopharmaceuticals, specializing in the development of groundbreaking medicines to address some of the world's most pressing medical challenges. From its vast portfolio, Bristol-Myers Squibb focuses on creating treatments that profoundly improve and extend lives, targeting conditions like cancer, cardiovascular diseases, and immune disorders. This sharp focus on specific therapeutic areas allows the company to leverage its research acumen and clinical expertise fully. It consistently nurtures innovation through robust investment in research and development, collaborating with universities, research institutes, and biotechnology firms to stay ahead in a fiercely competitive field. Making money in the pharmaceutical sector involves a delicate dance of science, strategic marketing, and regulatory navigation, and Bristol-Myers Squibb has mastered this choreography. The company generates revenue primarily through the sale of its prescription medications, which follow a comprehensive journey from initial R&D and clinical trials through rigorous regulatory approval processes and, ultimately, to market launch. Blockbuster drugs like Opdivo and Eliquis, which cater to oncology and cardiovascular therapy markets respectively, bring in substantial revenue, driven by their efficacy and the global demand for effective treatments. Moreover, the company's commitment to expanding its pipeline ensures a steady flow of new products and maintains its competitive edge. By continually evaluating its portfolio and capitalizing on emerging medical needs, Bristol-Myers Squibb not only sustains its financial health but also solidifies its reputation as a leader in transforming patients' futures.

BMY Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
33.5%
=
Operating Profit
16.1B
/
Revenue
48B
What is the Operating Margin of Bristol-Myers Squibb Co?

Based on Bristol-Myers Squibb Co's most recent financial statements, the company has Operating Margin of 33.5%.

Back to Top